drugset / Trial / NCT04807751

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

NCT04807751

Phase 1 Completed 60 enrolled LEO Pharma
RandomizedSingle-groupDouble-blindOther

Summary

Participants will have study medicine applied by site staff- delgocitinib cream or vehicle, and then exposed to UV light. The trial is designed to find out if delgocitinib cream can cause skin photoallergy after UV-light exposure in people with healthy skin.

Timeline

Start
2021-03-25
Primary completion
2021-07-30
Completion
2021-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Delgocitinib Small molecule 20 unknown Topical

Indications

No indication recorded.